WHO Guidelines Webinar

Cervical cancer remains a major public health challenge globally, with a disproportionate burden in low- and middle-income countries (LMICs), despite the availability of effective prevention strategies and the global commitment to its elimination. Countries should screen 70% of women with a high-performance test twice in life to be on the pathway to elimination.

Cervical screening not only involve collecting and testing a sample, for a program to be cost-effective, women who screen positive should complete the screening continuum (triage, treatment, follow-up).

Current high-performance HPV tests offer the possibility of identifying individual or grouped carcinogenic HPV types. HPV limited or extended genotyping offers a built-in molecular triage that allows for simple stratification and prioritized management of HPV-positive women according to the risk for cervical pre-cancer and cancer granted by specific HPV types groups. 

In this webinar, recommendations primarily for the general population of women, with consideration of program capacity, particularly in relation to follow-up and treatment services, as well as preferred screening strategies under varying resource conditions that can be applied in different settings will be presented.